Insider Buy: Rigel Pharmaceuticals
5:20PM ET 6/13/2022 MT NewswiresRaul R Rodriguez, Director, CEO, President, on June 09, 2022, executed a purchase for 1,000,000 shares in Rigel Pharmaceuticals (RIGL) for $688,400....
Quotes Snapshot > RIGL
Rigel Pharmaceuticals Inc RIGL:NASDAQ
Last Price$1.25NASDAQ Closing Price as of 4:00PM ET 7/01/22
Today's Change+0.12(10.62%)
Bid (Size)$1.17 (9)
Ask (Size)$1.20 (21)
Day Low / High$1.11 - 1.29
Volume5.0 M
Read more news Recent News
BMO Lowers Rigel Pharmaceuticals' Price Target to $3 From $7, Maintains Outperform Rating
10:37AM ET 6/09/2022 MT NewswiresRigel Pharmaceuticals (RIGL) has an average rating of outperform and price targets ranging from $1 to $7, according to analysts polled by Capital IQ. (MT...
B. Riley Lowers Rigel Pharmaceuticals' Price Target to $1.25 from $4 After Disappointing Trial Data on Fostamatinib, Keeps Neutral Rating
8:53AM ET 6/09/2022 MT NewswiresB. Riley lowered Rigel Pharmaceuticals' (RIGL) price target to $1.25 from $4 after the company announced Wednesday that its top-line efficacy and safety...
--Citigroup Downgrades Rigel Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $0.80 From $7
7:18AM ET 6/09/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
Rigel Pharmaceuticals: A Status Check
7:53AM ET 5/31/2022 Seeking Alphaargenx: A Very Good Start For Vyvgart
7:33AM ET 5/25/2022 Seeking AlphaRigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call Transcript
11:01PM ET 5/03/2022 Seeking AlphaRigel Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
5:03PM ET 5/03/2022 Seeking AlphaCompany Profile
Business DescriptionRigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 1180 Veterans Boulevard South San Francisco, California 94080-1985 |
| Phone | +1.650.624.1100 |
| Number of Employees | 158 |
| Recent SEC Filing | 06/23/2022 8-K |
| President, Chief Executive Officer & Director | Raul R. Rodriguez |
| Chief Financial Officer & Executive Vice President | Dean L. Schorno |
| Chief Medical Officer & Executive Vice President | Wolfgang Dummer |
| Chief Commercial Officer & Executive VP | David Santos |
Company Highlights
| Price Open | $1.12 |
| Previous Close | $1.13 |
| 52 Week Range | $0.64 - 4.55 |
| Market Capitalization | $215.1 M |
| Shares Outstanding | 172.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/02/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.48 |
| Beta vs. S&P 500 | N/A |
| Revenue | $44.5 M |
| Net Profit Margin | -99.89% |
| Return on Equity | -219.06% |
Analyst Ratings as of 06/08/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |